• DOI:10.1124/JPET.103.051797
Corpus ID: 18753440

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

@article{Millan2003TheNM,
  title={The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways},
  author={M. Millan and A. Gobert and F. Lejeune and A. Dekeyne and A. Newman-Tancredi and V. Pasteau and J.‐M. Rivet and D. Cussac},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2003},
  volume={306},
  pages={954 - 964}
}

M. Millan, A. Gobert, +5 authors D. Cussac

Published 2003

Chemistry, Medicine

Journal of Pharmacology and Experimental Therapeutics

Agomelatine (S20098) displayed pKi values of 6.4 and 6.2 at native (porcine) and cloned, human (h)5-hydroxytryptamine (5-HT)2C receptors, respectively. It also interacted with h5-HT2B receptors (6.6), whereas it showed low affinity at native (rat)/cloned, human 5-HT2A (<5.0/5.3) and 5-HT1A (<5.0/5.2) receptors, and negligible (<5.0) affinity for other 5-HT receptors. In antibody capture/scintillation proximity assays, agomelatine concentration dependently and competitively abolished h5-HT2C… CONTINUE READING

View on ASPET

jpet.aspetjournals.org

Save to Library

Create Alert

Cite

Launch Research Feed